Table 1. Baseline breast cancer characteristics in the study population (diagnosis during the period 2006–2012).
| N | % | |
| Breast cancer cases | 1531 | 100.0 |
| Age at diagnosis, mean (SD) | 59.8 (6.1) | |
| Years of diagnosis | ||
| 2006–2009 | 810 | 52.9 |
| 2010–2012 | 721 | 47.1 |
| Ductal carcinoma in situ (DCIS) | 285 | 18.6 |
| Invasive cancer | 1246 | 81.4 |
| Invasive cancers | 1246 | 100.0 |
| of which: | ||
| T stage 1 | 812 | 65.2 |
| T stage 2+ | 373 | 29.9 |
| Treated neoadjuvantly | 61 | 4.9 |
| N stage 0 | 836 | 67.1 |
| N stage 1+ | 346 | 27.8 |
| Treated neoadjuvantly | 61 | 4.9 |
| Missing | 3 | 0.2 |
| Grading: | ||
| Grade I | 327 | 26.2 |
| Grade II | 631 | 50.6 |
| Grade III | 284 | 22.8 |
| Missing | 4 | 0.3 |
| Receptor status: | ||
| Hormone receptor-positive, HER2-negative | 901 | 72.3 |
| HER2-positive | 213 | 17.1 |
| Triple-negative | 118 | 9.5 |
| Missing | 14 | 1.1 |
| Type of surgery: | ||
| Breast-conserving therapy | 862 | 69.2 |
| Breast-conserving therapy + mastectomy | 96 | 7.7 |
| Mastectomy | 281 | 22.6 |
| Missing | 7 | 0.6 |
| Indication for chemotherapy: | ||
| Yes | 608 | 48.8 |
| No | 577 | 46.3 |
| Treated neoadjuvantly | 61 | 4.9 |
| Type of surgery (including DCIS): | 1531 | 100.0 |
| Breast-conserving therapy | 1049 | 68.5 |
| Breast-conserving therapy + mastectomy | 134 | 8.8 |
| Mastectomy | 341 | 22.3 |
| Missing | 7 | 0.5 |
HER2, human epidermal growth factor receptor 2; SD, standard deviation